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Abstract: Resistant hypertension is a major opportunity for prevention of cardiovascular disease. Despite widespread 
dissemination of consensus guidelines, most patients are uncontrolled with approaches that assume that all patients are the 
same. 
Causes of resistant hypertension include 1) non-compliance 2) consumption of substances that aggravate hypertension 
(such as salt, alcohol, nonsteroidal anti-inflammatory drugs, licorice, decongestants) and 3) secondary hypertension.  
Selecting the appropriate therapy for a patient depends on finding the cause of the hypertension. Once rare causes have 
been eliminated (such as pheochromocytoma, licorice, adult coarctation of the aorta), the cause will usually be found by 
intelligent interpretation (in the light of medications then being taken) of plasma renin and aldosterone. 
If stimulated renin is low and the aldosterone is high, the problem is primary aldosteronism, and the best treatment is 
usually aldosterone antagonists (spironolactone or eplerenone; high-dose amiloride for men where eplerenone is not 
available). If the renin is high, with secondary hyperaldosteronism, the best treatment is angiotensin receptor blockers or 
aliskiren. If the renin and aldosterone are both low the problem is over-activity of renal sodium channels and the treatment 
is amiloride. This approach is particularly important in patients of African origin, who are more likely to have low-renin 
hypertension. 
Keywords: Resistant hypertension, renin, amiloride, primary hyperaldosteronism, renal sodium channel, African-American, 
Stroke belt. 
  Uncontrolled hypertension represents a failure of the 
usual approach of evidence-based guidelines. Despite regular 
updating and wide dissemination, even the best consensus 
guidelines achieve abysmal results. In Canada, where the 
guidelines are admirably administered and updated annually, 
the proportion of hypertensive patients controlled to <140/90 
has failed to increase from the 17% controlled in 1997 [1] to 
the 15.8% controlled in 2007 [2]. (This may have changed 
recently.) Control rates have been somewhat better (29%) in 
the United States, and even worse (< 10%) in Europe [3]. In 
my view, a major reason for the failure of such guidelines is 
that they tend to make the fallacious assumption that all 
patients should be treated the same way, with insufficient 
attention to tailoring the therapy to the cause of hypertension 
in patients with resistant hypertension. 
  The consequences of this failure are enormous, and 
represent a major opportunity for prevention of the conse-
quences of hypertension, particularly stroke. A particular 
tragedy is the failure of physicians to recognize that patients 
of African origin are more likely to have specific causes of 
low-renin hypertension that require specific therapies [4, 5]. 
This probably accounts for the observation by Howard et al. 
[6] that black patients in the stroke belt are more likely to be 
aware of and more likely to be treated for hypertension, more 
likely to be treated more intensively, but less likely to be 
controlled. The result of this is that African-Americans 
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have twice the risk of stroke[7]; the tragedy is that this is 
preventable.  
CAUSES OF RESISTANT HYPERTENSION 
  The causes of resistant hypertension are summarized in 
Table 1. Non-compliance with medication is common, and 
approximately half of patients will admit to non-compliance 
[8]. Compliance is better with medications that have less 
adverse effects [9, 10]. Followup with pharmacists may be 
needed to determine if prescriptions have been filled. If the 
patient is taking the prescribed medication, a careful history 
is required to determine if the blood pressure is being 
aggravated by consumption of substances such as excess 
salt, licorice, alcohol, non-steroidal anti-inflammatory drugs, 
decongestants or oral contraceptives. (Sulindac, which spares 
renomedullary prostaglandins, is the only NSAID that does 
not aggravate hypertension [11]. Naproxcinod shows pro-
mise for the future [12]. ) If none of these causes is apparent, 
the patient requires investigation for secondary hypertension. 
  Some 90% of strokes among hypertensive patients are 
attributable to uncontrolled hypertension [13]. In London, 
Ontario, a concerted effort to increase detection and 
treatment of hypertension reduced stroke by half, between 
1978 and 1983 [14]. This was accomplished by a large effort 
on the part of the Department of Family Medicine [15, 16], 
in concert with a Hypertension Clinic using stimulated 
plasma renin levels [17] to detect causes of secondary 
hypertension. In 20 years [18] I found only 52 patients with 
pheochromocytoma, 9 from licorice, 9 from hypernephroma, 
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case of atherosclerotic occlusion above and below the renal 
arteries, mimicking bilateral renal artery stenosis [19].  
  Once those rare causes of hypertension are eliminated, 
the remainder are to be found in the renin-angiotensin-
aldosterone axis, or in abnormalities of the renal tubular 
sodium channel (Fig. 1). Patients with high levels of renin 
and secondary hyperaldosteronism require investigation for 
renal or renovascular causes, and may need renal decom-
pression (for example, relief of a ureteric stricture) or 
revascularization [20]. Their medical therapy is primarily 
with angiotensin receptor antagonists (ARBs) or aliskiren. 
(Inhibitors of angiotensin converting enzyme are not as 
effective because of angiotensin II escape pathways such as 
chymase and cathepsin; they may act mainly by increasing 
nitric oxide release via blockade of bradykinin inactivation, 
and can be thought of as similar to long-acting nitrates.) 
Patients with low renin and high levels of aldosterone have 
primary aldosteronism, which accounts for 20% of resistant 
hypertension [21]. It is crucial to recognize that the impera-
tive to find the cause of resistant hypertension is not mainly 
about finding cases for surgeons, it is about choosing appro-
priate medical therapy [22]; this is particularly important in 
patients of African origin. 
PATIENTS OF AFRICAN ORIGIN 
  Although most US physicians are aware that African-
American patients have lower levels of plasma renin on 
average, seldom are the reasons given sufficient conside-
ration. There are important lessons to be learned from Sub-
Saharan Africa [5]. Rayner and colleagues have found in the 
Khoi San people (indigenous people of Southern Africa, 
thought to be candidates for the original homo sapiens) that 
20% have a polymorphism of the renal tubular epithelial 
sodium channel (a variant of Liddle’s syndrome) that causes 
salt and water retention and hypertension (personal com-
munication, 2009). Though this ability to retain salt and 
water may have been adaptive to survival in the Kalahari 
Desert, it causes severe hypertension in conditions of 
abundance of salt and water. This polymorphism accounts 
for 6% of hypertension in South African blacks [23], and a 
related polymorphism was found by the group of McGregor 
in London, UK, in 6% of black patients (mostly from the 
Caribbean) [24, 25]. These conditions are specifically treated 
with amiloride [24]. (Although thiazide and other diuretics 
may lower blood pressure in these conditions, they would be 
more likely to aggravate potassium depletion.) 
  In addition to the selective advantage of salt and water 
retention for survival in Sub-Saharan Africa, there may have 
been additional selective pressure favouring salt and water 
retention (and therefore low-renin hypertension) in the 
Atlantic crossing on slave ships, and then for survival 
working in the cotton fields [26]. 
  Besides variants of the renal sodium channel, patients of 
African origin are more likely to have primary aldosteronism 
due to bilateral hyperplasia of the adrenal cortex [27]. It is 
increasingly recognized that solitary adrenal nodules that are 
surgically curable represent a shrinking proportion of 
primary aldosteronism, and that therapy is medical in most 
cases. Biglieri et al. first described four cases of primary 
adrenocortical hyperplasia in 1984 [28]. At that time we had 
already identified approximately 70 cases, of which 10 
required adrenalectomy because they could not be controlled 
medically. Of those 10 cases 4 were black (whereas less than 
1% of our patients were black), suggesting a major dispro-
portion of this condition among black patients. One of these 
was from Swaziland; the other 3 came from North Buxton, a 
black community in Southwestern Ontario, descended from 
escaped slaves who came to Canada via the Underground 
Railroad.  
ADRENOCORTICAL HYPERPLASIA IS USUALLY 
BILATERAL 
  Between 1980 and 1983, with Dr. Albert Driedger, we 
studied 100 patients with stimulated plasma renin levels 
<1ng/ml/hr. with iodocholesterol scanning before and after 
dexamethasone suppression. We were looking for patients 
with unilateral adenomas, who might benefit from adrena-
lectomy. To our astonishment, not a single case had a unila-
teral hot adrenal gland. Approximately 70% had bilateral hot 
adrenals, and 30% were normal. I suspect that some or many 
of the normal cases were missed cases of Liddle’s syndrome 
and variants, as in those days we did not have access to mea-
surement of plasma aldosterone. In our experience, therefore, 
most primary aldosteronism is due to bilateral hyperplasia.  
  Two forms of familial primary aldosteronism have so far 
been reported; in both these conditions nodular hyperplasia, 
with nodules large enough to resemble (and be confused 
with) adenomas, is common [29]. The first was dexame-
Table 1.  Causes of Resistant Hypertension 
1. Non-compliance 
  Half of patients will admit it [8] 
  Better with drugs that have less adverse effects [9, 10]  
2. Consumption of substances that aggravate hypertension 
  Salt, licorice, NSAID’s, oral contraceptives, decongestants 
  Sulindac is the only NSAID that doesn’t raise blood pressure [11] 
3. Secondary hypertension 
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thasone-suppressible hypertension, first described by 
Laidlaw’s group [30], and then elegantly elucidated by 
Lifton et al. to be due to a chimeric gene; a fusion of the 5’ 
regulatory region of 11-B hydroxylase to aldosterone syn-
thase, with the result that aldosterone is driven by ACTH 
[31]. This condition is treated with low-dose dexamethasone. 
The second is not dexamethasone-suppressible, and is linked 
to 7p22 [29, 32].  
 Table  2 lists some of the causes of low-renin hyperten-
sion. 
 Table  3 shows our algorithm for sorting out the cause and 
the primary treatment for patients with resistant hyper-
tension, once rare causes such as pheochromocytoma, lico-
rice and aortic coarctation are excluded. Plasma renin and 
aldosterone are best measured in a stimulated condition, as 
described by Dawson’s group [41]. If the patient is already 
taking medication that stimulates renin, such as diuretics, 
ACE inhibitors or ARB’s, then further stimulation is not 
needed. However, the results must be interpreted in the light 
of the medication being taken. ARB’s (and probably alis-
kiren) are particularly effective at suppressing aldosterone 
production, so a patient with a low or low-normal renin level 
and a high or high-normal aldosterone level while taking an 
ARB probably has primary aldosteronism, for the purposes 
of adjusting medical therapy. Further investigation would be 
needed to justify adrenalectomy.  
 
Table 2.  Causes of Low-Renin Hypertension 
Conn’s syndrome  (unilateral surgically curable adenoma – if it exists) 
Primary adrenocortical hyperplasia [5, 27, 28] 
Familial hyperaldosteronism 
Type I Dexamethasone-suppressible hypertension [30, 33];  chimeric 
gene causing ACTH-dependent aldosterone production  
Treat with low-dose dexamethasone 
Type II Linked to chromosome 7p22 [29] 
Treat with aldosterone antagonists [34]; rarely surgical 
Gordon’s syndrome [35]  
        treat with salt restriction 
Renal tubular sodium channel mutations or alteration  
Liddle’s syndrome [36] and variants [24, 25, 37]   
       5-6% of HT in blacks low aldo and renin; treat with amiloride 
Adducin polymorphisms [38] 
Endogenous ouabain [39]  
        low aldo and renin; treat with amiloride (possibly rostafuroxin) 
GIP dependent cortisol excess with nodular hyperplasia [40] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Central role of the renin-angiotensin-aldosterone axis in resistant hypertension 
In normal homeostasis, renin is released under conditions of low blood pressure or dehydration; that activates aldosterone release, which 
causes salt and water retention, and excretion of potassium, magnesium, zinc and other ions. Disorders of this physiology can cause 
hypertension with three patterns of renin and aldosterone levels: Primary hyperaldosteronism causes salt and water retention, feeding back to 
suppress renin. Renal or renovascular causes of hypertension cause elevated renin with secondary hyperaldosteronism. Abnormalities of the 
renal tubular epithelial sodium channel (Liddle’s syndrome and other polymorphisms of the renal sodium channel, or adducin), cause salt and 
water retention and suppress both renin and aldosterone 122    Current Cardiology Reviews, 2010, Vol. 6, No. 2  J. David Spence 
SOME PATIENTS HAVE MORE THAN ONE FORM 
OF SECONDARY HYPERTENSION 
  Not included in the algorithm are the very rare cases with 
more than one cause of hypertension. In 20 years as the 
physician of last resort for resistant hypertension for a 
catchment area with a population of approximately 2 million 
(and with some referrals from far beyond), I saw about 15 
patients with primary aldosteronism who had gone on to 
develop renal artery stenosis. These patients thus had both 
primary and secondary hyperaldosteronism, and required 
both aldosterone antagonists and ARBs (a combination that 
would usually be avoided because of the risk of hyper-
kalemia). One patient of mine with both primary and secon-
dary hyperaldosteronism has primary aldosteronism and 
polycystic kidneys, with plasma aldosterone levels that are 
50 times the upper limit of normal. This is a rare but recog-
nized syndrome; there is some evidence that potassium 
depletion from primary aldosteronism exacerbates renal 
cysts [42, 43]. It seems likely that some patients with 
Liddle’s variants might also have other causes of secondary 
hypertension. Such cases require thoughtful interpretation of 
all the clinical data including the levels of renin and 
aldosterone, and the medications being taken at the time of 
renin and aldosterone sampling. 
 Egan  et al. [44] recently published a randomized trial 
showing that measurement of plasma renin improved therapy 
of resistant hypertension. In my view it is better to measure 
both renin and aldosterone so that renal tubular sodium chan-
nel variants and other factors affecting the function of the 
renal sodium channel (adducin [38], endogenous ouabain 
[39]) can be differentiated from primary aldosteronism. The 
reason this is important is that medical therapy for primary 
aldosteronism is best with aldosterone antagonists (spirono-
lactone, or for men, eplerenone), because they counteract the 
other adverse effects of spironolactone on the vasculature 
beyond elevation of blood pressure: inflammation, remodel-
ling and fibrosis [32, 34, 45], On the other hand, salt and 
water retention based on enhanced function of the sodium 
channel, with low levels of renin and aldosterone, are best 
treated with amiloride (or possibly rostafuroxin [38]). The 
appropriate selection of amiloride or aldosterone antagonists 
leads not only to more physiological therapy, but may also 
improve adherence, by preventing the adverse effects of 
kaliuretic diuretics.  
SUMMARY AND CONCLUSIONS 
  Uncontrolled hypertension is a major preventable cause 
of stroke, renal failure, heart failure and dementia. To reduce 
the burden of this problem it is important to identify the 
underlying cause of resistant hypertension so that the 
appropriate therapy can be selected. Once rare causes of 
hypertension have been excluded, measuring the levels of 
plasma renin and aldosterone will identify the cause in most 
cases, for purposes of medical therapy. The most neglected 
causes of resistant hypertension, which particularly afflict 
patients of African origin, are primary aldosteronism (usua-
lly due to bilateral hyperplasia), best treated with aldosterone 
antagonists, and variants of the renal tubular sodium channel, 
which are specifically treated with amiloride. 
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